Wells Fargo & Company MN Has $263,000 Position in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Wells Fargo & Company MN increased its position in shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) by 144.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,493 shares of the biotechnology company’s stock after buying an additional 48,177 shares during the period. Wells Fargo & Company MN owned 0.16% of Infinity Pharmaceuticals worth $263,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. FMR LLC raised its stake in Infinity Pharmaceuticals by 3.7% in the fourth quarter. FMR LLC now owns 1,188,976 shares of the biotechnology company’s stock worth $1,605,000 after buying an additional 42,476 shares in the last quarter. Nationwide Fund Advisors raised its stake in Infinity Pharmaceuticals by 211.8% in the first quarter. Nationwide Fund Advisors now owns 96,918 shares of the biotechnology company’s stock worth $313,000 after buying an additional 65,838 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Infinity Pharmaceuticals by 394.6% in the first quarter. Russell Investments Group Ltd. now owns 208,238 shares of the biotechnology company’s stock worth $673,000 after buying an additional 166,138 shares in the last quarter. Acadian Asset Management LLC raised its stake in Infinity Pharmaceuticals by 689.0% in the first quarter. Acadian Asset Management LLC now owns 585,232 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 511,057 shares in the last quarter. Finally, Tudor Investment Corp Et Al raised its stake in Infinity Pharmaceuticals by 738.5% in the fourth quarter. Tudor Investment Corp Et Al now owns 165,998 shares of the biotechnology company’s stock worth $224,000 after buying an additional 146,200 shares in the last quarter. 76.49% of the stock is currently owned by institutional investors.

Infinity Pharmaceuticals, Inc. (NASDAQ INFI) opened at 1.43 on Thursday. The stock has a 50 day moving average price of $1.67 and a 200-day moving average price of $2.13. The stock has a market cap of $72.13 million, a P/E ratio of 715.00 and a beta of 2.63. Infinity Pharmaceuticals, Inc. has a 12-month low of $0.84 and a 12-month high of $3.84.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $19.60 million. During the same quarter in the previous year, the company earned ($0.82) EPS. The company’s quarterly revenue was down 99.9% compared to the same quarter last year. On average, equities analysts expect that Infinity Pharmaceuticals, Inc. will post ($0.84) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/markets/wells-fargo-company-mn-has-263000-position-in-infinity-pharmaceuticals-inc-nasdaqinfi/1234064.html.

INFI has been the topic of a number of analyst reports. Zacks Investment Research lowered Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. Six research analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and an average price target of $1.17.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Want to see what other hedge funds are holding INFI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana
Chicago Cubs Strengthen Rotation Through Trade for Jose Quintana


Leave a Reply

 
© 2006-2017 BBNS.